Smaller sized doses for perioral treatment than for upper facial applications are employed because the oral musculature responds more strongly to precisely the same BTX-A dosing. Only one planning of botulinum toxin type B (MyoBloc®/NeuroBloc®) exists. Its sole indicator and FDA approval lies in treatments of cervical dystonia. Xeomin® https://botulinum-toxins30519.ktwiki.com/1529340/fascination_about_botulinum_toxin_death